{"id":5616,"date":"2025-08-11T07:37:00","date_gmt":"2025-08-11T11:37:00","guid":{"rendered":"https:\/\/www.bvimedical.com\/us\/?p=5616"},"modified":"2025-08-06T09:18:02","modified_gmt":"2025-08-06T13:18:02","slug":"bvi-and-airgas-join-forces-to-improve-surgical-access-and-patient-outcomes-in-retinal-care","status":"publish","type":"post","link":"https:\/\/www.bvimedical.com\/us\/bvi-and-airgas-join-forces-to-improve-surgical-access-and-patient-outcomes-in-retinal-care\/","title":{"rendered":"BVI Delivering on the Promise of Expansion in Retinal Surgery: Nationwide Ophthalmic Gas Launch"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>Vitreoretinal surgeons can now benefit from access to BVI&#8217;s high-quality ISPAN<sup>TM<\/sup> ophthalmic gases, supporting the critical needs of advanced retinal procedures.<\/li>\n\n\n\n<li>This latest development leverages BVI\u2019s U.S. distribution network to ensure faster, more efficient delivery to surgeons and clinics.<\/li>\n<\/ul>\n\n\n\n<p>WALTHAM, Mass., August 11, 2025 \u2013 BVI Medical, a leading global ophthalmic device company at the forefront of advancements in eye surgery, today announced its official launch of ISPAN<sup>TM<\/sup> ophthalmic gases. &nbsp;This is the first ever introduction by BVI of retinal gases for the US market.<\/p>\n\n\n\n<p>This marks another major milestone during a period of accelerating momentum for BVI. Recently, BVI received US FDA approval of the innovative laser and endoscopy glaucoma surgical system, Leos<strong>\u2122<\/strong>. With its initial roots in the cataract segment of ophthalmology, these recent developments are building BVI\u2019s presence in the glaucoma and retina markets as well.<\/p>\n\n\n\n<p>The high-quality ISPAN<sup>TM<\/sup> ophthalmic gases, such as sulfur hexafluoride (SF\u2086) and perfluoropropane (C\u2083F\u2088), used in retinal tamponade procedures, will be more readily available for vitreoretinal surgeons, clinics, and hospitals via BVI\u2019s network throughout the United States.<\/p>\n\n\n\n<p>\u201cOphthalmic gases are essential tools in vitreoretinal surgery,\u201d said Shervin Korangy, President &amp; CEO of BVI. \u201cWe are excited to expand our offering in retinal care. This is another step in our global expansion and ISPAN compliments our existing broad range of single-use instruments for the US retina market.\u201d<\/p>\n\n\n\n<p>Ophthalmic gases are primarily used by vitreoretinal surgeons to provide a temporary tamponade following procedures for conditions such as retinal detachment repair. These gases play a crucial role in maintaining retinal positioning during healing, directly impacting surgical outcomes and patient recovery.<\/p>\n\n\n\n<p><strong>About BVI Medical<\/strong><\/p>\n\n\n\n<p>BVI\u00ae is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients\u2019 vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.<\/p>\n\n\n\n<p>To learn more about BVI Medical and its mission to advance the future of vision, visit <a href=\"https:\/\/www.bvimedical.com\">https:\/\/www.bvimedical.com<\/a><\/p>\n\n\n\n<p><strong>***<\/strong><\/p>\n\n\n\n<p><strong>Press Contact<\/strong><\/p>\n\n\n\n<p>David Chavez<\/p>\n\n\n\n<p>Global Communications Lead<\/p>\n\n\n\n<p><a href=\"mailto:dchavez@bvimedical.com\">dchavez@bvimedical.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., August 11, 2025 \u2013 BVI Medical, a leading global ophthalmic device company at the forefront of advancements in eye surgery, today announced its official launch of ISPANTM ophthalmic gases. &nbsp;This is the first ever introduction by BVI of retinal gases for the US market. This marks another major milestone during a period of [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"1,11,2870,2873,2876,2879","_relevanssi_noindex_reason":"","footnotes":""},"categories":[17],"tags":[],"class_list":["post-5616","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/posts\/5616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/comments?post=5616"}],"version-history":[{"count":0,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/posts\/5616\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/media?parent=5616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/categories?post=5616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bvimedical.com\/us\/wp-json\/wp\/v2\/tags?post=5616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}